MYD88 and bacterial infectious disease: Indeed, in this study, MYD88 inhibitor treatment stopped the progression of alveolar bone loss induced by Pg. Ultimately, osteocyte-specific drug delivery systems would need to be developed because systemic MYD88 inhibition will increase the host’s susceptibility to bacterial infection and impair bacterial clearance by the host immune system76–78.